Future studies will assess the efficacy of targeting TRAF3IP2 as a monotherapy or a combination therapy in robust animal models of heterogeneous primary GBM, with reductions in tumor size, angiogenesis, cerebral edema, and improvements in overall and disease-free survival as critical endpoints. The gene discussed is TRAF3IP2; the disease is neoplasm.